Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free ENLV Stock Alerts

Enlivex Therapeutics (ENLV) Competitors

Enlivex Therapeutics logo
$0.71 +0.00 (+0.59%)
Closing price 06/8/2026 04:00 PM Eastern
Extended Trading
$0.72 +0.00 (+0.53%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ENLV vs. AMPH, CYRX, ESPR, LBRX, and KURA

Should you buy Enlivex Therapeutics stock or one of its competitors? MarketBeat compares Enlivex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enlivex Therapeutics include Amphastar Pharmaceuticals (AMPH), CryoPort (CYRX), Esperion Therapeutics (ESPR), LB Pharmaceuticals (LBRX), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry.

How does Enlivex Therapeutics compare to Amphastar Pharmaceuticals?

Enlivex Therapeutics (NASDAQ:ENLV) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Enlivex Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 2,210.28%. Amphastar Pharmaceuticals has a consensus target price of $24.00, indicating a potential upside of 23.78%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Enlivex Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Amphastar Pharmaceuticals
1 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.88

Enlivex Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Enlivex Therapeutics' net margin of 0.00%. Enlivex Therapeutics' return on equity of 248.08% beat Amphastar Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Enlivex TherapeuticsN/A 248.08% 206.39%
Amphastar Pharmaceuticals 11.00%15.12%7.14%

Enlivex Therapeutics has higher earnings, but lower revenue than Amphastar Pharmaceuticals. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A$1.24B-$0.55N/A
Amphastar Pharmaceuticals$719.89M1.19$98.09M$1.6611.68

In the previous week, Amphastar Pharmaceuticals had 6 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enlivex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amphastar Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Enlivex Therapeutics beats Amphastar Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Enlivex Therapeutics compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Enlivex Therapeutics has lower revenue, but higher earnings than CryoPort. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CryoPort$176.18M4.43$78.30M$1.3511.47
Enlivex TherapeuticsN/AN/A$1.24B-$0.55N/A

CryoPort presently has a consensus price target of $15.11, indicating a potential downside of 2.38%. Enlivex Therapeutics has a consensus price target of $16.50, indicating a potential upside of 2,210.28%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than CryoPort.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CryoPort
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

CryoPort has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 10.1% of CryoPort shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CryoPort has a net margin of 41.57% compared to Enlivex Therapeutics' net margin of 0.00%. Enlivex Therapeutics' return on equity of 248.08% beat CryoPort's return on equity.

Company Net Margins Return on Equity Return on Assets
CryoPort41.57% -7.92% -4.79%
Enlivex Therapeutics N/A 248.08%206.39%

In the previous week, CryoPort had 3 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 4 mentions for CryoPort and 1 mentions for Enlivex Therapeutics. CryoPort's average media sentiment score of 0.34 beat Enlivex Therapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CryoPort
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enlivex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

CryoPort beats Enlivex Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Enlivex Therapeutics has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$403.14M2.01-$22.68M-$0.06N/A
Enlivex TherapeuticsN/AN/A$1.24B-$0.55N/A

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 1.6% of Esperion Therapeutics shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to Enlivex Therapeutics' net margin of 0.00%. Enlivex Therapeutics' return on equity of 248.08% beat Esperion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Esperion Therapeutics0.12% -0.14% 0.12%
Enlivex Therapeutics N/A 248.08%206.39%

In the previous week, Enlivex Therapeutics had 1 more articles in the media than Esperion Therapeutics. MarketBeat recorded 1 mentions for Enlivex Therapeutics and 0 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 0.00 equaled Enlivex Therapeutics'average media sentiment score.

Company Overall Sentiment
Esperion Therapeutics Neutral
Enlivex Therapeutics Neutral

Esperion Therapeutics currently has a consensus target price of $5.54, indicating a potential upside of 75.87%. Enlivex Therapeutics has a consensus target price of $16.50, indicating a potential upside of 2,210.28%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Esperion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Esperion Therapeutics
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Enlivex Therapeutics beats Esperion Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Enlivex Therapeutics compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

1.0% of Enlivex Therapeutics shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

LB Pharmaceuticals presently has a consensus target price of $38.40, suggesting a potential upside of 30.61%. Enlivex Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 2,210.28%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than LB Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LB Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Enlivex Therapeutics' return on equity of 248.08% beat LB Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
LB PharmaceuticalsN/A N/A N/A
Enlivex Therapeutics N/A 248.08%206.39%

In the previous week, Enlivex Therapeutics had 1 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 1 mentions for Enlivex Therapeutics and 0 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.00 equaled Enlivex Therapeutics'average media sentiment score.

Company Overall Sentiment
LB Pharmaceuticals Neutral
Enlivex Therapeutics Neutral

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LB PharmaceuticalsN/AN/A-$25.20M-$1.73N/A
Enlivex TherapeuticsN/AN/A$1.24B-$0.55N/A

Summary

Enlivex Therapeutics beats LB Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Kura Oncology?

Enlivex Therapeutics (NASDAQ:ENLV) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Enlivex Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 2,210.28%. Kura Oncology has a consensus price target of $25.58, indicating a potential upside of 198.87%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Kura Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Kura Oncology
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Enlivex Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

Enlivex Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Enlivex Therapeutics' return on equity of 248.08% beat Kura Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Enlivex TherapeuticsN/A 248.08% 206.39%
Kura Oncology -411.19%-141.95%-43.28%

In the previous week, Kura Oncology had 12 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 13 mentions for Kura Oncology and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 beat Kura Oncology's score of -0.15 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enlivex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kura Oncology
0 Very Positive mention(s)
0 Positive mention(s)
12 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Enlivex Therapeutics has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A$1.24B-$0.55N/A
Kura Oncology$67.48M11.26-$278.67M-$3.35N/A

Summary

Enlivex Therapeutics beats Kura Oncology on 11 of the 15 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENLV vs. The Competition

Export
MetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$168.54M$2.96B$6.48B$11.99B
Dividend YieldN/A1.70%2.67%5.58%
P/E Ratio-1.3017.6823.6923.74
Price / SalesN/A302.68514.83109.27
Price / CashN/A56.1726.9937.25
Price / Book0.093.8310.436.78
Net Income$1.24B$75.85M$3.57B$337.51M
7 Day Performance-15.97%-2.00%0.27%-2.34%
1 Month Performance-7.25%-5.85%3.25%1.88%
1 Year Performance-24.02%14.03%22.24%25.55%

Enlivex Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENLV
Enlivex Therapeutics
2.522 of 5 stars		$0.71
+0.6%		$16.50
+2,210.3%		-26.2%$168.54MN/AN/A70
AMPH
Amphastar Pharmaceuticals
3.6559 of 5 stars		$18.45
+0.2%		$24.50
+32.8%		-25.4%$812.19M$719.89M11.111,976
CYRX
CryoPort
3.4034 of 5 stars		$15.74
-1.6%		$14.69
-6.7%		+121.1%$805.93M$176.18M11.661,186
ESPR
Esperion Therapeutics
3.5479 of 5 stars		$3.14
+0.3%		$5.54
+76.4%		+158.2%$805.76M$403.14MN/A200
LBRX
LB Pharmaceuticals
1.787 of 5 stars		$27.02
-3.6%		$38.40
+42.1%		N/A$803.81MN/AN/A16

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ENLV) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel